The association between methionine synthase A2756G polymorphism and hematological cancer

Background:Numerous studies have focused on the association of methionine synthase (MS) A2756G polymorphism and acute hematological cancer risk. However, the results remain inconsistent. Therefore, a meta-analysis was performed to derive a more precise estimate of the association between them. Methods: This meta-analysis involved 25 articles (26 studies) including 8641 hematological cancer patients and 15,498 controls. The pooled odds ratios (ORs) and their corresponding 95% confidence intervals (CIs) of the association between MS A2756G polymorphism and the risk of hematological cancer were calculated. Results: Overall, no significant increased risks were found between MS A2756G polymorphism and hematological cancer risk under allelic homozygote (GA vs AA: OR=0.98, 95% CI=0.89–1.07, P= .62), heterozygote (GG vs AA: OR=0.99, 95% CI= 0.85–1.15, P= .91), dominant (AG+GG vs AA: OR=0.99, 95% CI=0.90–1.08, P= .93), and recessive (GG vs AG+AA: OR=1.00, 95% CI=0.86–1.16, P= .97) models, respectively. In the stratified analyses by ethnicity and source of controls, there were still no significant associations between them in all genetic models. Conclusions: Therefore, these findings demonstrate that MS A2756G polymorphism may not be a risk factor for hematological cancer. Abbreviations: CIs = confidence intervals, HWE = Hardy-Weinberg equilibrium, MS = methionine synthase, MTHFR = methylenetetrahydrofolate reductase, MTRR = methionine synthase reductase, ORs = odds ratios, SNPs = single nucleotide polymorphisms.